Waters Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Udit Batra
- Full Time Employees
- 7,900
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 34 Maple Street Milford MA United States of America 01757
- IPO Date
- Nov 17, 1995
- CIK
- 0001000697
- Website
- waters.com
- Similar Companies
- Business
- Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.
Company News
Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript
Still Waters Bring Mixed Pre-Market Levels
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
Waters Corporation (WAT) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
Waters Corporation $WAT Shares Purchased by Benjamin Edwards Inc.
This Waters Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Waters Corporation to Present at the Wells Fargo Healthcare Conference
Bank of Nova Scotia Sells 3,735 Shares of Waters Corporation $WAT
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Assetmark Inc. Has $1.57 Million Stake in Waters Corporation $WAT
Dudley & Shanley Inc. Has $8.85 Million Stake in Waters Corporation $WAT
Waters (NYSE:WAT) Director Sells $1,442,930.44 in Stock
Waters Q2 Earnings Call Highlights
Waters Corporation $WAT Shares Acquired by Empowered Funds LLC
Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised